



Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases in Patients with Diabetes Mellitus

Guest Editor:

Dr. Nikolaos Kadoglou

Medical School, University of
Cyprus, 2029 Nicosia, Cyprus

Deadline for manuscript
submissions:

26 February 2024

Message from the Guest Editor

Dear Colleagues,

Diabetes mellitus (DM) has already evolved into an epidemic in developing countries, and especially in the western world. It is well-known that diabetic patients have a 2- to 4-fold higher risk for cardiovascular diseases (CVDs). Moreover, the presence of DM remarkably increases the incidence of cardiovascular events in patients with established CVDs despite the administration of optimum pharmaceutical therapy. The re-vascularization procedures in coronary and peripheral arteries are characterized by a higher incidence of complications in patients with DM than their non-diabetic counterparts. Therefore, there is still an increasing need to develop and apply more effective medications for primary and secondary prevention of CVDs (ischemic and non-ischemic) in the DM population.

The aim of the present Special Issue is to attract more than 10 high-quality papers that focus on drugs with potentiality to contribute to CVD prevention and treatment in diabetic patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com